Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Aren’t Crazy About Cidara Therapeutics Inc (CDTX) Anymore

Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the activity of those successful funds in these small-cap stocks. In the following paragraphs, we analyze Cidara Therapeutics Inc (NASDAQ:CDTX) from the perspective of those successful funds.

Is Cidara Therapeutics Inc (NASDAQ:CDTX) an outstanding investment now? Prominent investors are actually reducing their bets on the stock. The number of bullish hedge fund positions that are disclosed in regulatory 13F filings decreased by 2 in recent months. There were 7 hedge funds in our database with CDTX holdings at the end of September. At the end of this article we will also compare CDTX to other stocks including Enzymotec Ltd (NASDAQ:ENZY), GigOptix Inc (NYSEAMEX:GIG), and CAI International Inc (NYSE:CAI) to get a better sense of its popularity.

Follow Cidara Therapeutics Inc. (NASDAQ:CDTX)
Trade (NASDAQ:CDTX) Now!

We care about hedge fund sentiment because historically hedge funds’ stock picks delivered strong risk adjusted returns. There are certain segments of the market where hedge funds’ stock picks performed much better than its benchmarks. For instance, the 30 most popular mid-cap stocks among the best performing hedge funds returned 18% over the last 12 months outpacing S&P 500 Index by more than 10 percentage points. We developed this strategy 2.5 years ago and started sharing its picks in our quarterly newsletter. It bested the S&P 500 Index ETFs by delivering a solid 39% vs. 22% gain for its benchmarks.

Most Advanced Countries in Medicine

everything possible/

With all of this in mind, let’s review the recent action regarding Cidara Therapeutics Inc (NASDAQ:CDTX).

Hedge fund activity in Cidara Therapeutics Inc (NASDAQ:CDTX)

At Q3’s end, a total of 7 of the hedge funds tracked by Insider Monkey were bullish on this stock, a decline of 22% from the previous quarter. The graph below displays the number of hedge funds with bullish position in CDTX over the last 5 quarters. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

CDTX Chart

According to Insider Monkey’s hedge fund database, Frazier Healthcare Partners, led by Alan Frazier, holds the largest position in Cidara Therapeutics Inc (NASDAQ:CDTX). According to regulatory filings, the fund has a $15 million position in the stock, comprising 7.4% of its 13F portfolio. Sitting at the No. 2 spot is Aisling Capital, led by Dennis Purcell, which holds a $11.7 million position; 2.4% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors that are bullish consist of Joseph Edelman’s Perceptive Advisors, Kris Jenner, Gordon Bussard, Graham McPhail’s Rock Springs Capital Management and Hal Mintz’s Sabby Capital. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.